Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins
Dexcom, a medical device specialist, is poised to benefit from the growing weight-loss drug market as its continuous glucose monitoring (CGM) devices are often prescribed alongside GLP-1 weight loss drugs. The CGM market is underpenetrated, with over nine million eligible patients in the U.S. not using CGM devices.
Investors looking to capitalize on the weight-loss market can consider Dexcom, a medical device specialist. Dexcom develops and sells continuous glucose monitoring (CGM) devices for diabetes patients. Despite initial concerns that GLP-1 weight loss drugs would reduce the need for CGM devices, physicians often prescribe both together. A survey found that CGM usage grows faster among GLP-1 users. The CGM market is underpenetrated, with over nine million eligible patients in the U.S. not using CGM devices. Dexcom's financial results have improved substantially as CGM adoption grows, and the company can expand its market by entering new territories.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.